Boehringer Ingelheim increases access to clinical trial dataBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g3347 (Published 15 May 2014) Cite this as: BMJ 2014;348:g3347
- Zosia Kmietowicz
Boehringer Ingelheim has become the latest drug company to commit to releasing full data it holds on the clinical trials it has conducted on its products once they are approved or after their development has been abandoned.
In an announcement on 12 May the German company said that researchers will be able to request clinical study reports and other clinical documents, including de-identified patient level study data, through its website (trials.boehringer-ingelheim.com/trial_results.html).
The requests will have to be approved by an independent external review panel, and researchers will have to sign a data sharing agreement in which they promise to use the data only for the purpose of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial